Tags » MDR-TB

#Prevalence of drug- #resistant #tuberculosis and imputed burden in #SouthAfrica: a national and sub-national cross-sectional survey (Lancet Infect Dis., abstract)

Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey

Nazir Ahmed Ismail, FCPath, Lindiwe Mvusi, MBChB, Ananta Nanoo, MSc, Andries Dreyer, FCPath, Shaheed V Omar, PhD, Sanni Babatunde, PhD, Thabo Molebatsi, MPH, Martie van der Walt, PhD, Adeboye Adelekan, PhD, Varough Deyde, PhD, Chikwe Ihekweazu, FFPH†, Prof Shabir A Madhi, PhD† 382 more words


Report of India's First National Anti-Tuberculosis Drug Resistance Survey Released (24 March 2018)

On occasion of World Tuberculosis Day, the report of India’s first Nationally representative Anti-Tuberculosis Drug Resistance Survey (2014-2016) was released.

Background Information and Rationale:

India has more new tuberculosis (TB) patients annually than any other country globally,  797 more words


#Tuberculosis: #progress and #advances in development of new #drugs, #treatment regimens, and host-directed therapies (Lancet Infect Dis., abstract)

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

Simon Tiberi, MD, Nelita du Plessis, PhD, Prof Gerhard Walzl, FRCP, Michael J Vjecha, MD, Martin Rao, PhD, Prof Francine Ntoumi, FRCP, Prof Sayoki Mfinanga, PhD, Nathan Kapata, MPH, Prof Peter Mwaba, FRCP, Prof Timothy D McHugh, PhD, Prof Giuseppe Ippolito, FRCP, Prof Giovanni Battista Migliori, FRCP, Prof Markus J Maeurer, FRCP, Prof Alimuddin Zumla, FRCP… 265 more words


#Palliative #care for drug- #resistant #tuberculosis: when new drugs are not enough (Lancet Resp Med., abstract)

Palliative care for drug-resistant tuberculosis: when new drugs are not enough

Jennifer Hughes, Leigh Snyman

Published: 05 February 2018 / DOI: https://doi.org/10.1016/S2213-2600(18)30066-3

© 2018 Elsevier Ltd. 99 more words


WHO revises advice on use of delamanid drug in MDR-TB patients

In a Phase III trial, delamanid drug was found to be safe but the cure rate and mortality rate were not different between the group that received the delamanid drug for MDR-TB and the group that received a placebo. 528 more words


A glimmer of hope as India’s war on TB gets more funding

There is a glimmer of hope with India registering a slight drop in the number of new tuberculosis cases and TB deaths in 2016 compared with 2015. 454 more words


Drug Resistant TB on the rise in Manicaland

By Tariro Guwira

Mutare-Multi-drug resistant tuberculosis (MDR TB) cases have been on the rise in the province a Zimbabwe Network for people living with HIV (ZNNP+) official has revealed. 422 more words

Health Desk